CMLYM23075 // A052101 // Wallace
Basic Study Information
Purpose:
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving
a complete remission (CR) with rituximab works in older adult patients with mantle
cell lymphoma (MCL) who have not received treatment in the past (previously untreated).
Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells
to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current
standard of care is to continue administering the drug indefinitely until disease
progression. This continuous treatment comes with clinical as well as financial toxicity,
which could be especially detrimental in older patients. For patients who achieve
a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally
effective to stop treatment and restart zanubrutinib upon disease progression rather
than continuing indefinitely in previously untreated older adult patients with MCL.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Danielle Wallace
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search